Results 41 to 50 of about 146,874 (392)

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer [PDF]

, 2015
Neoadjuvant chemotherapy plus trastuzumab (NCT) increases the rate of pathological complete response (pCR) and event-free survival (EFS) compared to neoadjuvant chemotherapy (NC) alone in women with HER2 positive breast cancer (BC).
Ades, F, Ahmed, R, Asher, R, Beresford, M, De Azambuja, E, Gojis, O, Howell, SJ, Januszewski, A, Lewanski, C, Lythgoe, D, Macpherson, IRJ, Owadally, W, Palmieri, C, Riddle, P, Shah, D, Stanley, B, Yan, K   +16 more
core   +2 more sources

Trastuzumab: triumphs and tribulations [PDF]

Oncogene, 2007
The human epidermal growth factor receptor 2 (HER2) tyrosine kinase receptor is overexpressed in approximately 20-30% of human breast cancers, and is associated with reduced survival. Hence, numerous therapeutic strategies have been tested for their ability to target the HER2 protein.
Rita Nahta, Francisco J. Esteva
openaire   +3 more sources

Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis

Systematic Reviews, 2022
Introduction Trastuzumab, as the gold standard for HER2-positive BC treatment, was the first-line HER2 targeted drug. However, some studies reported patients benefited more from lapatinib and lapatinib plus trastuzumab therapy than standard trastuzumab ...
Ye Yuan, Xumei Liu, Yi Cai, Wenyuan Li
doaj   +1 more source

Regioselective and stoichiometrically controlled conjugation of photodynamic sensitizers to a HER2 targeting antibody fragment [PDF]

, 2014
The rapidly increasing interest in the synthesis of antibody–drug conjugates as powerful targeted anticancer agents demonstrates the growing appreciation of the power of antibodies and antibody fragments as highly selective targeting moieties.
Boyle, Ross W., Bryden, Francesca, Caddick, Stephen, Chudasama, Vijay, Maruani, Antoine, Savoie, Huguette, Smith, Mark E. B.   +6 more
core   +1 more source

Implications of subcutaneous or intravenous delivery of trastuzumab: further insight from patient interviews in the PrefHer study [PDF]

, 2015
BACKGROUND: The 2 Cohort randomised PrefHer trial examined the preferences of HER2+ve primary breast cancer patients for intravenous (IV) or subcutaneous (SC) delivery of trastuzumab via a Single Injectable Device (SID) or hand-held syringe (HHS).
Basch, C. Langridge, Ismael, J. Kilkerr, K. Monson, L. Fallowfield, Melichar, Piccart-Gebhart, Pivot, Pivot, S. Osborne, Samanta, Slamon, Stoner, V. Jenkins   +14 more
core   +1 more source

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.

New England Journal of Medicine, 2019
BACKGROUND Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor.
S. Modi, C. Saura, T. Yamashita, Yeon-Hee Park, Sung-Bae Kim, K. Tamura, F. André, H. Iwata, Yoshinori Ito, J. Tsurutani, J. Sohn, N. Denduluri, C. Perrin, K. Aogi, E. Tokunaga, S. Im, K. Lee, S. Hurvitz, J. Cortés, Caleb Lee, Shuquan Chen, Lin Zhang, J. Shahidi, A. Yver, I. Krop   +24 more
semanticscholar   +1 more source

Disrupting Circadian Rhythm via the PER1–HK2 Axis Reverses Trastuzumab Resistance in Gastric Cancer

Cancer Research, 2022
In trastuzumab-resistant HER2-positive gastric cancer, glycolysis fluctuates with a circadian oscillation regulated by the BMAL1–CLOCK–PER1–HK2 axis, which can be disrupted with a metformin-based chronotherapy to overcome trastuzumab resistance.
Jiao Wang, Qiong Huang, Xingbin Hu, Shuyi Zhang, Yu Jiang, Guangyu Yao, Kongzhen Hu, Xin Xu, B. Liang, Qijing Wu, Zhenfeng Ma, Yawen Wang, Chunlin Wang, Zhenzhen Wu, Xiaoxiang Rong, W. Liao, Min Shi   +16 more
semanticscholar   +1 more source

Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice [PDF]

British Journal of Cancer, 2021
AbstractTrastuzumab is a biologic therapy indicated for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer and metastatic gastric cancer. Trastuzumab was originally approved as an intravenous (IV) formulation but has since been developed for subcutaneous (SC) administration for patients with HER2-positive breast ...
Cornelius F. Waller, Julia Möbius, Adolfo Fuentes-Alburo   +2 more
openaire   +4 more sources

First-line therapy in HER2 positive metastatic breast cancer. Is the mosaic fully completed or are we missing additional pieces? [PDF]

, 2016
The discovery of human epidermal growth factor receptor 2 (HER2) and its role in the biology of breast cancer and the subsequent development of HER2-targeted therapies, have dramatically improved clinical outcomes for women with early-stage and advanced ...
Cognetti F., Fabi A., Malaguti P., Vari S.   +3 more
core   +2 more sources

Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer

New England Journal of Medicine, 2019
Background Patients who have residual invasive breast cancer after receiving neoadjuvant chemotherapy plus human epidermal growth factor receptor 2 (HER2)–targeted therapy have a worse prognosis than those who have no residual cancer.
G. von Minckwitz, Chiun-Sheng Huang, M. Mano, S. Loibl, E. Mamounas, M. Untch, N. Wolmark, P. Rastogi, A. Schneeweiss, A. Redondo, H. Fischer, W. Jacot, A. Conlin, C. Arce‐Salinas, I. Wapnir, C. Jackisch, M. DiGiovanna, P. Fasching, J. Crown, P. Wülfing, Z. Shao, E. R. Caremoli, Haiyan Wu, L. Lam, D. Tesarowski, M. Smitt, Hannah Douthwaite, S. Singel, C. Geyer   +28 more
semanticscholar   +1 more source